Cocrystal Pharma Inc
COCP
Company Profile
Business description
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
Contact
19805 North Creek Parkway
BothellWA98011
USAT: +1 877 262-7123
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
11
Stocks News & Analysis
stocks
AI stocks winners, laggards and losers for 2025
AI stocks flew high in 2025 despite year-end volatility. Palantir and Lam look overvalued, but opportunities remain.
stocks
12 picks for an income portfolio - Q4 2025 update
Eighteen months in and passive income growth has exceeded my target.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,092.70 | 25.50 | 0.28% |
| CAC 40 | 8,317.07 | 45.02 | -0.54% |
| DAX 40 | 25,262.38 | 0.74 | 0.00% |
| Dow JONES (US) | 49,504.07 | 237.96 | 0.48% |
| FTSE 100 | 10,113.12 | 11.48 | -0.11% |
| HKSE | 26,608.48 | 376.69 | 1.44% |
| NASDAQ | 23,671.35 | 191.33 | 0.81% |
| Nikkei 225 | 51,939.89 | 822.63 | 1.61% |
| NZX 50 Index | 13,683.29 | 12.96 | -0.09% |
| S&P 500 | 6,966.28 | 44.82 | 0.65% |
| S&P/ASX 200 | 8,759.40 | 25.80 | 0.30% |
| SSE Composite Index | 4,165.29 | 44.86 | 1.09% |